✨ Free AI Report
Caris Life Sciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Caris Life Sciences, Inc.
Company Research

Caris Life Sciences, Inc.: Business Overview, Financials & Competitive Analysis

Caris Life Sciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Solid). Strong growth trajectory in precision oncology with improving unit economics and path to sustainable profitability, but execution risks and payer reimbursement challenges warrant cautious positioning. Recent quarterly revenue of $181.4M exceeded expectations with 81% growth and strong profitability signals emerging, but the lack of current profitability and early-stage.

What is Caris Life Sciences, Inc.'s industry? Caris Life Sciences, Inc. (carislifesciences.com) operates in Precision Medicine / Molecular Diagnostics / Oncology Genomics. AskCyborg classifies Caris Life Sciences, Inc. under Precision Medicine / Molecular Diagnostics / Oncology Genomics in its company registry.

Caris Life Sciences is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The company is a rapidly-growing market leader in precision oncology lab testing, lev...

7/ 10Solid

Cyborg Score thesis

Strong growth trajectory in precision oncology with improving unit economics and path to sustainable profitability, but execution...

Read the full analyst-debate transcript →
Industry Precision Medicine / Molecular Diagnostics / Oncology Genomics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Caris Life Sciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Caris Life Sciences, Inc.

AskCyborg analysts argue the bull and bear cases for Caris Life Sciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Caris Life Sciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Caris Life Sciences, Inc. Overview

Pro stress-test →

Caris Life Sciences is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The company is a rapidly-growing market leader in precision oncology lab testing, leveraging AI and molecular profiling to drive personalized cancer treatment decisions.

Strategic Profile

Pro stress-test →

Caris generates revenue through molecular profiling services to healthcare providers, hospitals, and oncologists, charging fees for tests that analyze tumor samples to identify genetic alterations and biomarkers, with key revenue streams including individual test payments, subscription models, and partnerships with pharmaceutical companies. The company is experiencing strong momentum with 2024 revenue of $412.26 million, a 34.67% increase compared to 2023, positioning itself as a high-growth precision medicine player in oncology.

Competitive Landscape

Pro stress-test →

Key competitors include Personalis, Oncimmune, GnuBIO, Editas Medicine, and Personal Genome Diagnostics. Caris differentiates through comprehensive molecular profiling combined with proprietary AI/ML algorithms and strong relationships with oncologists and payers in the precision oncology space.

Industry Context

Caris Life Sciences, Inc. operates in Precision Medicine / Molecular Diagnostics / Oncology Genomics.

Key facts

Headquarters: Phoenix, US · Employees: 1,769 · Revenue: $412M (2024 annual); $649M (TTM) · Market cap: $5.8B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Caris Life Sciences, Inc..

  • Analyst consensus is "Strong Buy" with 12-month price target of $34.71, implying 55.58% upside from current levels
  • First post-IPO quarter materially exceeded consensus expectations with stronger pricing and volumes
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Stock trading near 52-week lows following recent correction
  • Q4 2025Earnings beat expectations with 81% YoY revenue growth
  • +1 moreTrack every material event for Caris Life Sciences, Inc. as it happens. Explore monitoring →
Get alerted when Caris Life Sciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PersonalisCancer genomics and molecular profiling→Editas MedicineCRISPR-based therapeutics→Personal Genome DiagnosticsTumor sequencing and cancer genomics→

Compare Caris Life Sciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Caris Life Sciences, Inc. operates in Precision Medicine / Molecular Diagnostics / Oncology Genomics. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Medicine / Molecular Diagnostics / Oncology Genomics research →
NEW · MCP server

Ask your AI assistant about Caris Life Sciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Caris Life Sciences, Inc. and its top competitor on Cyborg Score”
“What did Caris Life Sciences, Inc. do this quarter?”
“Is Caris Life Sciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Caris Life Sciences, Inc. do?+
Caris Life Sciences is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The company is a rapidly-growing market leader in precision oncology lab testing, lev...
What is Caris Life Sciences, Inc.'s Cyborg Score?+
Caris Life Sciences, Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Caris Life Sciences, Inc.'s main competitors?+
Named competitors include Personalis, Editas Medicine, Personal Genome Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Caris Life Sciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Caris Life Sciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Caris Life Sciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Medicine research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Personalis, Inc.